Clinical trials: Non-hodgkin Lymphoma
Acute Biphenotypic Leukemia, Acute Leukemia
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of care allogeneic hematopoietic stem cell transplantation for the…
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT07819396
- Testing
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Mantle Cell Lymphoma
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission
This phase I/II trial studies the side effects and best dose of ixazomib citrate (ixazomib) when given together with rituximab and to see how well they work after stem cell transplant in treating patients with mantle cell…
- Trial name
- NCT02632396
- Testing
- Ixazomib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Lymphoma
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003388
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell…
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Trial name
- NCT05121103
- Testing
- EZM0414
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Epizyme, Inc.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT05694364
- Testing
- Fludarabine, Cyclophosphamide, PRGN-3007
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Diffuse Large B-cell Lymphoma
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.
- Trial name
- NCT01990144
- Testing
- Bendamustine+Rituximab
- Where
- 52 sites in Italy
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who…
- Conditions
- EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma, Primary Testicular Lymphoma
- Trial name
- DuRIANS (NCT03212807)
- Testing
- Durvalumab, Lenalidomide
- Where
- 4 sites in Singapore
- Sponsor
- Singapore General Hospital
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL.
- Trial name
- NCT02500407
- Testing
- BTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 713 people
- Sponsor
- Genentech, Inc.
Tuberculosis (TB), Tuberculosis in Children
Shorter Treatment Regimen Implementation Evaluation Study
"Evaluation of the implementation of the shorter treatment regimen for children and adolescents with non-severe TB in Zambia" is a parallel and convergent mixed methods evaluation study of implementation and clinical outcomes of…
- Conditions
- Tuberculosis (TB), Tuberculosis in Children, Tuberculosis Treatment Effectiveness, Tuberculosis Active
- Trial name
- EvSTR (NCT07747792)
- Where
- Zambia
- Volunteers
- 175 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
- Trial name
- NCT01914744
- Testing
- Entecavir, Lamivudine
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Indolent B-cell Non-Hodgkin's Lymphoma
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT04533581
- Testing
- ME-401
- Where
- 30 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Kyowa Kirin Co., Ltd.
B-Cell Malignancies
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of…
- Trial name
- NCT04509700
- Testing
- Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib
- Where
- 105 sites in United States, Austria and 15 more
- Volunteers
- 112 people
- Sponsor
- Incyte Corporation
Leukemia, Non-Hodgkin's Lymphoma
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not responded to chemotherapy, surgery or radiation…
- Conditions
- Leukemia, Non-Hodgkin's Lymphoma, NHL
- Trial name
- NHL (NCT00515892)
- Testing
- Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy
- Where
- 3 sites in United States, Poland
- Volunteers
- 50 people
- Sponsor
- Cambridge Antibody Technology
B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic…
- Trial name
- NCT05157971
- Testing
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Daptomycin is a new antimicrobial agent which has activity against resistant Gram positive cocci including MRSA. The phase 3 clinical trials for skin and soft tissue infections (SSTI) with Staphylococci and Streptococci have…
- Conditions
- Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
- Trial name
- NCT00261807
- Testing
- Daptomycin 6mg/kg/day
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
The prognosis of pediatric patients with hematologic malignancies whose disease is primarily refractory or those who experience a chemotherapy resistant bone marrow relapse is extremely poor.
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00697671
- Testing
- NK Cell Infusion, Immunotherapy, Miltenyi Biotec CliniMACS device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma, Non-Hodgkin, HIV Infections
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
To determine the toxicity and effectiveness of adding sargramostim (recombinant granulocyte-macrophage colony stimulating factor; GM-CSF) to a standard chemotherapy drug combination (methotrexate, bleomycin, doxorubicin…
- Trial name
- NCT00000689
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.